Therefore, testing for BCR-ABL mutations in CD34+ CML stem/progenitor cells using validated sensitive assays like allele-specific PCR may be cost-effective and should be considered before the start of TKI therapy, particularly in patients who present in the late CP. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.